摘要
目的:观察二姜四神汤对腹泻型肠易激综合征的治疗效果。方法:选择60例西医诊断符合IBS罗马Ⅲ诊断标准,中医辨证符合《肠易激综合征中医诊疗共识意见》脾肾阳虚证的病例,采用随机对照试验,分为治疗组(二姜四神汤)和对照组(匹维溴铵片+口服酪酸梭菌活菌片)各30例,30天为1疗程,在治疗前、后统计中医症状积分及IBS-QOL量表积分以评估疗效及生活质量。结果:治疗组总有效率为90.0%,对照组为63.3%,两组比较,差异具有统计学意义(P<0.05)。两组治疗后IBS-QOL量表积分比较在焦虑不安、行为障碍、身体角色、社会功能的生活质量改善方面,治疗组均优于对照组,但在健康忧虑、挑食、性行为、人际关系的生活质量改善方面,治疗组与对照组无明显差别。结论:二姜四神汤治疗腹泻型肠易激综合征疗效肯定,值得推广应用。
Objective: To observe the curative effects of Erjiang Sishen Decoction on diarrhea-dominant irritable bowel syndrome( D-IBS). Methods: A total of 60 cases of patients were selected,all of whom were in accordance with IBS Roma III diagnostic standard by the western medicine and with Yang-deficiency of spleen and kidney based on the consensus of TCM in diagnosis and treatment of IBS by the TCM. A randomized controlled trail was adopted. And the patients were divided into treatment group( Erjiang Sishen Decoction) and controlled group( Pinaverium Bromide Tablet adding Oral Clostridium Butyricum Tablets),with 30 cases in each group,and 30 days as a treatment course. TCM syndrome scores and IBS-QOL scale scores before and after the treatment were recorded to evaluate the curative effects and quality of life. Results: The total effective rate was 90. 0% in the treatment group,while 63. 3% in the controlled group. There were statistically significant differences between the two groups( P0. 05). Based on IBS-QOL scale scores,the treatment group was superior to the controlled group in anxiety,behavior disorder,physical characters,and social functions,but the two groups were not obviously different in improvement of life quality in healthy concerns,picky eating,sexual behaviors and interpersonal relationship. Conclusions: Erjiang Sishen Decoction has definite curative effects in the treatment of D-IBS,which is worthy of popularization and applications.
出处
《四川中医》
2016年第7期85-88,共4页
Journal of Sichuan of Traditional Chinese Medicine
基金
上海市浦东新区中医药事业发展专项资金(编号:PDYNZJ2014-13)
关键词
二姜四神汤
腹泻型肠易激综合征
规范化临床验证
Erjiang Sishen Decoction
Diarrhea-dominant irritable bowel syndrome(D-IBS)
Standardized clinical validation